Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
February 29, 2024 16:05 ET
|
Vigil Neuroscience, Inc.
Poster highlights clinical overlap of ALSP and multiple sclerosis (MS) and details patients’ barriers to genetic testing WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience,...
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
February 07, 2024 16:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
January 03, 2024 16:30 ET
|
Vigil Neuroscience, Inc.
- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 - - Extends projected...
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
November 22, 2023 16:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
November 16, 2023 16:05 ET
|
Vigil Neuroscience, Inc.
- Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target engagement and downstream pharmacological activity at 20 mg/kg consistent...
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023 07:05 ET
|
Vigil Neuroscience, Inc.
– Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in ALSP on track for this quarter – – First participant dosed in Phase 1 study of VG-3927, the first and only small...
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
October 17, 2023 07:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 05, 2023 16:01 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
September 26, 2023 07:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
September 11, 2023 12:00 ET
|
Vigil Neuroscience, Inc.
- Complete Phase 1 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg - - On track...